In this randomized, double-blind, placebo-controlled, dose-finding adaptive phase 2a/2b trial, treatment with human recombinant alkaline phosphatase did not improve kidney function among critically ill patients with sepsis-associated acute kidney injury (AKI). Peter Pickkers, MD, PhD, of Radboud University Nijmegen Medical Center, the Netherlands, presents findings from the STOP-AKI trial at the European Society of Intensive Care Medicine (ESICM) 31st Annual Congress, LIVES 2018, on October 24 in Paris. Used with permission.
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
You currently have no searches saved.
You currently have no courses saved.